Loading...
XNYS
PFE
Market cap158bUSD
Oct 08, Last price  
27.82USD
1D
-0.64%
1Q
15.10%
Jan 2017
-9.72%
Name

Pfizer Inc

Chart & performance

D1W1MN
XNYS:PFE chart
P/E
20.41
P/S
2.53
EPS
1.36
Div yield, %
6.18%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
8.48%
Revenues
62.58b
-1.65%
48,371,000,00048,428,000,00048,296,000,00050,009,000,00067,057,000,00061,035,000,00054,657,000,00051,584,000,00049,605,000,00048,851,000,00052,824,000,00052,546,000,00053,647,000,00041,172,000,00041,651,000,00081,288,000,000100,330,000,00059,553,000,00063,627,000,00062,579,000,000
Net income
7.77b
-3.12%
11,024,000,0008,210,000,0008,024,000,0008,635,000,0008,268,000,0008,705,000,0009,787,000,00011,649,000,0009,080,000,0006,966,000,0007,215,000,00021,305,000,00011,153,000,00016,273,000,0009,159,000,00022,147,000,00031,365,000,0002,133,000,0008,020,000,0007,770,000,000
CFO
11.71b
-8.15%
17,594,000,00013,353,000,00018,238,000,00016,587,000,00011,454,000,00020,240,000,00017,054,000,00017,765,000,00016,883,000,00014,512,000,00015,901,000,00016,470,000,00015,827,000,00012,588,000,00014,403,000,00032,580,000,00029,267,000,0008,700,000,00012,744,000,00011,705,000,000
Dividend
Nov 06, 20260.43 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Related entities

Subsidiaries (146)
PFIZER IRELAND VENTURES UNLIMITED COMPANY
Pfizer Luxembourg Global Holdings S.a r.l.
Pfizer Manufacturing Austria GmbH
Pfizer Netherlands International Finance B.V.
PFIZER OVERSEAS LLC
Pfizer PFE AsiaPac Holding B.V.
Pfizer PFE Eastern Investments B.V.
PFIZER PFE GLOBAL HOLDINGS B.V.
PFIZER PHARMACEUTICALS GLOBAL B.V.
PFIZER PRODUCTS INDIA PRIVATE LIMITED
PFIZER R&D UK LIMITED
PFIZER SL
PFIZER SPECIALTY UK LIMITED
PFIZER TRAE HOLDINGS KFT.
PHARMACIA & UPJOHN COMPANY LLC
Upjohn Finance B.V.
WARNER-LAMBERT COMPANY LLC
WYETH MEDICA G CASTLE
WYETH PHARMACEUTICALS INDIA PRIVATE LIMITED

Key people

Albert Bourla
Chairman of the Board, Chief Executive Officer · since 2020
Executive Vice President, Chief Financial Officer · since 2022
Alexandre De Germay
Executive Vice President, Chief International Commercial Officer · since 2023
Executive Vice President, Chief Digital and Technology Officer · since 2019
Douglas Lankler
Executive Vice President, Chief Legal Officer · since 2025
Aamir Malik
Executive Vice President, Chief US Commercial Officer · since 2023
Michael Mcdermott
Executive Vice President, Chief Global Supply Officer · since 2022
Payal Sahni
Executive Vice President, Chief People Experience Officer · since 2022
Executive Vice President, Chief Corporate Affairs Officer · since 2019
Chris Boshoff
Chief Scientific Officer, President - Research & Development · since 2025
Lead Independent Director · since 2019
Ronald Blaylock
Independent Director · since 2017
Independent Director · since 2024
Susan Desmond-Hellmann
Independent Director · since 2020
Independent Director · since 2015
Independent Director · since 2019
Independent Director · since 2020
Suzanne Johnson
Independent Director · since 2007
Dan Littman
Independent Director · since 2018
Independent Director · since 2020
IPO date
Jan 17, 1944
Employees
83,000
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
235 EAST 42ND STREET
NEW YORK, NY 10017
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT